Treatment of Graves' ophthalmopathy

Abstract

Graves' ophthalmopathy is an inflammatory disease with primary involvement of the extraocular muscles and the orbit. It encompasses the most common extra-thyroid manifestation in patients with Graves-Basedow disease. The underlying cause is molecular mimicry with the TSH receptor in ocular fibroblasts, leading to an immuno-mediated pathogenesis. Glucocorticoids at high doses are the cornerstone in moderate-severe cases. However, some patients are corticorresistant or intolerant. In recent years, therapeutic novelties have been described in terms of the dosage of the immunosuppressive treatments used, as well as the emergence of biological therapy in this field. The objective of this review is to update the treatment of Graves' ophthalmopathy, as well as to present alternative options in patients resistant or intolerant to glucocorticoids.

Keywords: Enfermedad de Graves-Basedow; Glucocorticoides; Glucocorticoids; Graves-Basedow disease; Graves’ ophthalmopathy; Inflamación orbitaria; Orbitopathy; Orbitopatía; Rituximab; Teprotumumab; Tocilizumab.